21 Apr 2020 - Cashwerkz (ASX:CWZ) newly appointed CEO, Jon Lechte talks about what attracted him to the role, and plans to drive growth for cash and fixed income products in a more uncertain economic environment.
15 Apr 2020 - MLC Senior Economist Bob Cunneen discusses the ongoing impact of the coronavirus on markets including central bank and government measures.
06 Apr 2020 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about its new drug application with the US FDA for Technegas and applications beyond pulmonary embolism in chronic chronic obstructive pulmonary ( COPD ) and asthma.
26 Mar 2020 - Lithium Consolidated Mineral Exploration Limited (ASX:LI3) Managing Director Andrew Haythorpe provides an update on the company's new WA projects prospective for gold, nickel and base metals, board changes and plans to improve the company’s prospects.
31 Mar 2020 - BluGlass Limited (ASX:BLG) Managing Director and CEO,Giles Bourne, talks about the company's 1:1 non-renounceable rights issue, the need to fund its technology through to commercialisation, independent validation of its RPCVD technology and its response to COVID-19.
31 Mar 2020 - Cynata Therapeutics Limited (ASX:CYP) Managing Director, Dr Ross MacDonald, talks 1H20 results, upcoming Phase 2 clinical trials, licensing and strategy to build the company's Cymerus cell therapy platform.
30 Mar 2020 - XTEK Limited (ASX:XTE) Managing Director Philippe Odouard talks 1H20 results, the company's front-line products for the Australian Defence Force and police forces, US strategy and outlook.
26 Mar 2020 - Cashwerkz Limited (ASX:CWZ) Executive Chairman John Nantes talks about the company's 1H20 results, new partners to the platform, outlook for the second half and impact of COVID-19.
18 Mar 2020 - First Graphene Limited (ASX:FGR) Executive Director and CFO, Peter Youd, talks about the company's 1H20 results, progress with key customer trials and work at the Graphene Engineering & Innovation Centre (GEIC) in Manchester, UK.
13 Mar 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker talks 1H20 results progress with the company's lead product Zolpimist, the spay version of Sanofi’s blockbuster insomnia drug Ambien and focus for 2020.
